Publications by authors named "Marjolein Sikkema"
The Efficacy of an Over-the-Counter Multivitamin and Mineral Supplement to Prevent Infections in Patients With Inflammatory Bowel Disease in Remission With Immunomodulators and/or Biological Agents: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Inflamm Bowel Dis
September 2024
Article Synopsis
- Patients with inflammatory bowel disease (IBD) treated with immunomodulators or biologics face a higher risk of infections and often experience malnutrition and vitamin deficiencies.* -
- A clinical trial was conducted with 320 IBD patients to assess if a daily multivitamin and mineral supplement could lower infection rates compared to a placebo over a 24-week period.* -
- The study's results showed no significant difference in infection rates between the two groups, indicating that the supplement did not reduce the risk of infections for patients in remission while on IBD treatments.*
Background: Regular colonoscopic surveillance for detection of dysplasia is recommended in longstanding inflammatory bowel disease (IBD), however, its sensitivity is disputed. Screening accuracy may increase by using a biomarker-based surveillance strategy.
Methods: A case-control study was performed to determine the prognostic value of DNA ploidy and p53 in IBD-related neoplasia.
Background & Aims: As the risk of esophageal adenocarcinoma (EAC) and mortality in patients with Barrett's esophagus (BE) are important determinants of the potential yield and cost-effectiveness of BE surveillance, clarification of these factors is essential. We therefore performed a systematic review and meta-analysis to determine the incidence of EAC and mortality due to EAC in BE under surveillance.
Methods: Databases were searched for relevant cohort studies in English language that reported EAC risk and mortality due to EAC in BE.
Objectives: Surveillance of patients with Barrett's esophagus (BE) aims at early detection and treatment of neoplastic changes, particularly esophageal adenocarcinoma (EAC). The histological evaluation of biopsy samples has its limitations, and biomarkers may improve early identification of BE patients at risk for progression to EAC. The aim of this study was to determine the predictive value of p53, Ki67, and aneuploidy as markers of neoplastic progression in BE.
View Article and Find Full Text PDF